Study: NMOSD Treated with Rituximab and Eculizumab Has Lower Risk of Relapse
A recent study has demonstrated that neuromyelitis optica spectrum disorder (NMSOD) patients treated with eculizumab have a lower risk of adjudicated relapse compared to those treated with placebo. This study…